Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.

[1]  D. DeMets,et al.  Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age , 2021, Family Medicine and Community Health Journal.

[2]  H. Noels,et al.  Platelet Abnormalities in Chronic Kidney Disease and Their Implications for Antiplatelet Therapy. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[3]  S. Yusuf,et al.  Polypill with or without Aspirin in Persons without Cardiovascular Disease. , 2020, The New England journal of medicine.

[4]  C. Reid,et al.  Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggest aspirin did not improve outcomes in older adults with chronic kidney disease. , 2020, Kidney international.

[5]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[6]  P. Ridker.  Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? , 2018, The New England journal of medicine.

[7]  Suzanne G. Orchard,et al.  Effect of Aspirin on Disability‐free Survival in the Healthy Elderly , 2018, The New England journal of medicine.

[8]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[9]  L. Gray,et al.  Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. , 2016, Atherosclerosis.

[10]  M. Tonelli,et al.  Cause of Death in Patients with Reduced Kidney Function. , 2015, Journal of the American Society of Nephrology : JASN.

[11]  A. Webster,et al.  Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.

[12]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[13]  A. Zanchetti,et al.  Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. , 2010, Journal of the American College of Cardiology.

[14]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[15]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[16]  M. Landray,et al.  First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[18]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[19]  G. Remuzzi.  BLEEDING IN RENAL FAILURE , 1988, The Lancet.